AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 31 min read$BBNX

Hopman Mark sold $102K of BBNX

Hopman Mark (Chief Commercial Officer) sold 5,327 shares of Beta Bionics, Inc. (BBNX) at $19.11 ($0.10M total) on 2026-09-02.

Original reporting
SEC EDGAR · Hopman Mark
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BBNX
Neutral
high confidence
Mentioned
$BBNX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BBNXNeutralLow
01

Why it matters

The disclosed sale is modest and does not materially affect Beta Bionics' valuation.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming regulatory or clinical trial news not disclosed here.

Relevance 4/10Novelty 4/10Timing: post‑market filing on Sep 3

Background

Form 4 filings disclose insider transactions; investors track them for signals of insider confidence.

Company-level read

Ticker impact

$BBNXNeutralHigh confidence
Context

Chief Commercial Officer Hopman Mark sold 5,327 shares for $101.8K, reducing his stake to 124,027 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to market cap and typical insider trading volumes.

Market effects

Sector

None; biotech sector unchanged.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor for further disposals.

Key entities

  • Company
    Beta Bionics, Inc.

    Medical device maker listed on Nasdaq (BBNX).

  • Executive
    Hopman Mark

    Chief Commercial Officer of Beta Bionics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BBNX insider trading history →

Related articles

JUL 29
$BBNXMedAI 8/10

Beta Bionics posts Q2 beats on 38% sales growth

Beta Bionics (Nasdaq:BBNX) reported Q2 results that beat consensus. For the quarter ended June 30, 2026, it posted a $23.4M loss (53¢/share) on $32.0M revenue, with sales up about 38% versus a year earlier. DME sales were $20.4M (+9%) and PBP sales $11.6M (+153%). It reaffirmed 2026 revenue guidance of $131M to $136M.

drugdeliverybusiness.com4 min
JUL 29
$BBNXMed

Beta Bionics (Nasdaq: BBNX) lifts Q2 sales to $32M amid ongoing losses

Beta Bionics (Nasdaq: BBNX) reported Q2 2026 net sales of $32.0M, up from $23.2M a year earlier, driven by its iLet insulin delivery device and single-use consumables. Six-month sales were $59.6M. The company reported a six-month net loss of $45.3M. As of June 30, 2026 it had $44.3M cash and $180.8M in U.S. Treasury investments, and an FDA Warning Letter in January 2026 cited quality system and reporting deficiencies.

stocktitan.net4 min
JUN 1
$BBNXMedAI 8/10

Robbins LLP is Investigating Allegations that the Officers and Directors of Beta Bionics, Inc. (BBNX) Violated Securities Laws and Breached Fiduciary Duties to Shareholders

Robbins LLP said it is investigating whether Beta Bionics Inc. (NASDAQ: BBNX) officers and directors violated securities laws or breached fiduciary duties. After Beta Bionics’ Jan. 8, 2026 preliminary Q4 2025 results, it expected at least 5,581 new patient starts (+36% YoY), below analyst expectations and down from the prior quarter’s 68% growth; the stock fell over 35% on Jan. 9.

wallstreet-online.de3 min